SCHEMBL3150082

SCHEMBL3150082

CC(=O)OC[C@H]1OC(n2cnc3c(=O)[nH]cnc32)[C@@H](OC(C)=O)[C@@H]1OC(C)=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.64
▸ ALDH1A1 P00352 3/20 0.64
▸ TP53 P04637 1/20 0.64
▸ MAPT P10636 1/20 0.64
▸ TDP1 Q9NUW8 1/20 0.64
▸ PRKAB2 O43741 1/20 0.56
▸ PRKAG1 P54619 1/20 0.56
▸ PRKAA2 P54646 1/20 0.56
▸ PRKAA1 Q13131 1/20 0.56
▸ PRKAG3 Q9UGI9 1/20 0.56
▸ PRKAG2 Q9UGJ0 1/20 0.56
▸ PRKAB1 Q9Y478 1/20 0.56
▸ GSK3A P49840 2/20 0.54
▸ RPS6KA3 P51812 2/20 0.54
▸ MAPK14 Q16539 2/20 0.54
▸ THRB P10828 1/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ HIF1A Q16665 1/20 0.52
▸ P2RX3 P56373 1/20 0.52
▸ TYMP P19971 4/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24191242 1.00 LMNA (0.64) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL10048818 1.00 LMNA (0.64) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL10001659 1.00 LMNA (0.64) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL14943053 1.00 LMNA (0.64) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL10017765 1.00 LMNA (0.64) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL20857280 0.91 ALDH1A1 (0.54) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL7060133 0.91 ALDH1A1 (0.54) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL9658521 0.91 ALDH1A1 (0.54) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL2619734 0.90 ALDH1A1 (0.51) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL13597937 0.90 ALDH1A1 (0.51) LMNAALDH1A1TP53MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0852499-B1 THERAPEUTIC AZIDE COMPOUNDS UNIV GEORGIA RES FOUND (US) 2010-03-03 — — EP disclosed
US-6949521-B2 Therapeutic azide compounds THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2005-09-27 — — US disclosed
US-20010036930-A1 Therapeutic azide compounds UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. 2001-11-01 — — US disclosed
EP-0852499-A1 THERAPEUTIC AZIDE COMPOUNDS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 1998-07-15 — — EP disclosed
WO-1997009052-A1 THERAPEUTIC AZIDE COMPOUNDS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 1997-03-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010036930-A1 Therapeutic azide compounds ADA, ADK, DCK LMNA 1731/4885ALDH1A1 685/4885TP53 4305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback